Same-day administration of AMD drugs

Article

It is possible to administer verteporfin and ranibizumab on the same day without adverse events, according to study results published in the December issue of the British Journal of Ophthalmology.

It is possible to administer verteporfin PDT (Visudyne) and ranibizumab (Lucentis) on the same day without adverse events, according to study results published in the December issue of the British Journal of Ophthalmology.

Professor Ursula Schmidt-Erfurth of the Universitätsklinik für Augenheilkunde und Optometrie at the University of Vienna, Austria and colleagues conducted a prospective, open-label, multicentre study, treating patients suffering from classic or occult CNV secondary to AMD with standard fluence verteporfin at baseline and months three, six and nine, and with ranibizumab 0.5 mg at baseline and months one, two and three.

At nine months, no severe vision loss from either inflammation or uveitis had occurred. There were cases of mild/moderate ocular adverse events, but no systemic adverse events. The mean BCVA improved by 6.9 letters at four months and by 2.4 letters at nine months: at this point, lesions were inactive, and all macular oedema and subretinal fluid had resolved.

The researchers concluded that same-day administration of verteporfin and ranibizumab was a safe and effective treatment for CNV.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.